ArticleCureus2025
Stabilization of Symptomatic Bone Marrow Metastases in Breast Cancer: A Case Report of Two Patients Treated With Trastuzumab Deruxtecan.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Symptomatic bone marrow infiltration (BMI) in breast cancer is exceedingly rare and often associated with poor prognosis due to cytopenias and limited therapeutic options. We report two elderly patients with a history of hormone receptor-positive, HER2-negative breast cancer who presented with pancytopenia years after initial treatment. Bone marrow biopsy revealed HER2-low metastatic relapse. Treatment with trastuzumab deruxtecan (T-DXd) led to unexpectedly rapid and complete hematologic recovery after only two cycles, with both patients remaining stable and free of marrow disease for over two years. These cases demonstrate the remarkable efficacy and tolerability of T-DXd in this uncommon and challenging clinical scenario, highlighting its potential as a valuable therapeutic option in HER2-low breast cancer with BMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.